Inkemia IUCT Group launches initial public offering on Alternative Stock Market
This is the second Catalan biotechnology company to take this step, after AB-Biotics. They have just closed a round of funding valued at €1.3 millions.
By Biocat
Inkemia IUCT Group, the holding group of biotechnology and high-technology SMEs based in Mollet del Vallès (Barcelona), has announced that their stock will be traded on the Alternative Stock Market (MAB) as of tomorrow. This is the second Catalan biotech company to be traded on the MAB. To guide them through this process, the group has hired Estratelis Advisors, a firm specializing in financial markets.
This decision was made after closing a round of funding valued at €1.3 millions, which will go towards strengthening the company’s financial structure and offsetting investment in technology and international expansion. 92% of the capital increase was acquired by new shareholders and 8% by previous shareholders. The group currently has more than 130 shareholders, surpassing the minimum established by the MAB.
Inkemia IUCT Group saw non-financial revenue of €4.8 millions in 2011, up 23% from the previous year. Founded in 1997, their main business is based on exploiting knowledge by licensing their own patents and know-how, customized R&D contracts and other technological services. Their main areas of expertise are drug discovery and development, industrial biotechnology and green chemistry. To this end, the group is made up of three fully owned companies: IUCT SA, the division that directly generates and exploits the group’s main product, which is knowledge; IUCT Emprèn SL, the entrepreneurial division that brings together companies they hold stock in and spin-offs; and IUCT Espais SL, the division that manages facilities and assets.
In November, IUCT Emprèn, through their Knowledge Capital Fund, took a share in Enemce Pharma, which develops improved repositioned drugs for cardiovascular therapy. They also hold a minority share in Plasmia Biotech and Phyture Biotech.